Association of an impaired bone marrow microenvironment with secondary poor graft function after allogeneic hematopoietic stem cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 10, 2013, Pages 1465-1473

  Kong, Yuan ^a   Chang, Ying Jun ^a   Wang, Ya Zhe ^a   Chen, Yu Hong ^a   Han, Wei ^a   Wang, Yu ^a   Sun, Yu Qian ^a   Yan, Chen Hua ^a   Wang, Feng Rong ^a   Liu, Yan Rong ^a   Xu, Lan Ping ^a   Liu, Dai Hong ^a   Huang, Xiao Jun ^a,b  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b Tsinghua University   (China)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Bone marrow; Microenvironment; Poor graft function; Secondary

Indexed keywords

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW; BONE MARROW MICROENVIRONMENT; CELL POPULATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIAL PROGENITOR CELL; FEMALE; GRAFT DYSFUNCTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MICROENVIRONMENT; MONONUCLEAR CELL; PANCYTOPENIA; PROSPECTIVE STUDY; RISK FACTOR; SHORT TANDEM REPEAT;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW; MICROENVIRONMENT; POOR GRAFT FUNCTION; SECONDARY;

ADOLESCENT; ADULT; BONE MARROW; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84884173108     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.07.014     Document Type: Article

References (44)

1. Larocca A., Piaggio G., Podestà M., et al. Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. Haematologica 2006, 91:935-940.
2. Liu X., Wu M., Peng Y., et al. Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: a pilot prospective study. Cell Transplant 2013, [Epub ahead of print].
3. Dominietto A., Raiola A.M., van Lint M.T., et al. Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol 2001, 112:219-227.
4. Olsson R., Remberger M., Schaffer M., et al. Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transplant 2013, 48:537-543.
5. Bittencourt H., Rocha V., Filion A., et al. Granulocyte colony-stimulating factor for poor graft function after allogeneic stem cell transplantation: 3 days of G-CSF identifies long-term responders. Bone Marrow Transplant 2005, 36:431-435.
6. Lee K.H., Lee J.H., Choi S.J., et al. Failure of trilineage blood cell reconstitution after initial neutrophil engraftment in patients undergoing allogeneic hematopoietic cell transplantation: frequency and outcomes. Bone Marrow Transplant 2004, 33:729-734.
7. Petersdorf E.W., Hansen J.A., Martin P.J., et al. Major histocompatibility complex class I alleles and antigens in hematopoietic-cell transplantation. NEngl J Med 2001, 345:1794-1800.
8. Remberger M., Watz E., Ringdén O., et al. Major ABO blood group mismatch increases the risk for graft failure after unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:675-682.
9. Sierra J., Storer B., Hansen J.A., et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood 1997, 89:4226-4235.
10. Tavassoli M., Friedenstein A. Hemopoietic stromal microenvironment. Am J Hematol 1983, 15:195-203.
11. Dexter T.M., Allen T.D., Lajtha L.G. Conditions controlling the proliferation of haemopoietic stem cells invitro. JCell Physiol 1977, 91:335-344.
12. Goron M.Y. Human haemopoietic stem cell assays. Blood Rev 1993, 7:190-197.
13. Damon L.E., Rugo H.S., Ries C.A., et al. Post-remission cytopenias following intense induction chemotherapy for acute myeloid leukemia. Leukemia 1994, 8:535-541.
14. Koç O.N., Gerson S.L., Cooper B.W., et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. JClin Oncol 2000, 18:307-316.
15. del Cañizo M.C., Lopez N., Vazquez L., et al. Hematopoietic damage prior to PBSCT and its influence on hematopoietic recovery. Haematologica 1999, 84:511-516.
16. Domenech J., Gihana E., Dayan A., et al. Haemopoiesis of transplanted patients with autologous marrows assessed by long-term marrow culture. Br J Haematol 1994, 88:488-496.
17. del Cañizo C., Lopez N., Caballero D., et al. Haematopoietic damage persists 1 year after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999, 23:901-905.
18. Migliaccio A.R., Migliaccio G., Johnson G., et al. Comparative analysis of hematopoietic growth factors released by stromal cells from normal donors or transplanted patients. Blood 1990, 75:305-312.
19. Marsh J.C., Chang J., Testa N.G., et al. The hematopoietic defect in aplasticanemia assessed by long-term marrow culture. Blood 1990, 76:1748-1757.
20. Papadaki H.A., Gibson F.M., Rizzo S., et al. Assessment of bone marrow stem cell reserve and function and stromal cell function in patients with autoimmune cytopenias. Blood 2000, 96:3272-3275.
21. Scadden D.T. The stem-cell niche as an entity of action. Nature 2006, 441:1075-1079.
22. Calvi L.M., Adams G.B., Weibrecht K.W., et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003, 425:841-846.
23. Ellis S.L., Grassinger J., Jones A., et al. The relationship between bone, hemopoietic stem cells, and vasculature. Blood 2011, 118:1516-1524.
24. Ding L., Saunders T.L., Enikolopov G., et al. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature 2012, 481:457-462.
25. Wacholder S., Silverman D.T., McLaughlin J.K., et al. Selection of controls in case-control studies, III: design options. Am J Epidemiol 1992, 135:1042-1050.
26. Huang X.J., Liu D.H., Liu K.Y., et al. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 2009, 15:257-265.
27. Huang X.J., Chang Y.J. Unmanipulated HLA-mismatched/haploidentical blood and marrow hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:197-204.
28. Zhu H.H., Zhang X.H., Qin Y.Z., et al. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood 2013, 121:4056-4062.
29. Lu D.P., Dong L., Wu T., et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006, 107:3065-3073.
30. Yan C.H., Liu D.H., Liu K.Y., et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 2012, 119:3256-3262.
31. Huang X.J., Zhu H.H., Chang Y.J., et al. The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. Blood 2012, 119:5584-5590.
32. Xu L.P., Huang X.J., Guo N.L., et al. Detection of cytomegalovirus infection by polymerase chain reaction in hematopoietic stem cell transplantation recipients. Zhong Hua Xue Ye Xue Za Zhi 2003, 24:407-409.
33. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980, 69:204-217.
34. Thomas E.D., Storb R., Clift R.A., et al. Bone-marrow transplantation (second of two parts). NEngl J Med 1975, 292:895-902.
35. Mangi M.H., Mufti G.J. Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies. Blood 1992, 79:198-205.
36. Perez-Atayde A.R., Sallan S.E., Tedrow U., et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997, 150:815-821.
37. Corselli M., Chin C.J., Parekh C., et al. Perivascular support of human hematopoietic stem/progenitor cells. Blood 2013, 121:2891-2901.
38. Nagasawa T., Omatsu Y., Sugiyama T. Control of hematopoietic stem cells by the bone marrow stromal niche: the role of reticular cells. Trends Immunol 2011, 32:315-320.
39. Bautch V.L. Stem cells and the vasculature. Nat Med 2011, 17:1437-1443.
40. Yang B., Gu W., Peng B., et al. High level of circulating endothelial progenitor cells positively correlates with serum vascular endothelial growth factor in patients with renal cell carcinoma. JUrol 2012, 188:2055-2061.
41. Nilsson S.K., Johnston H.M., Whitty G.A., et al. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood 2005, 106:1232-1239.
42. Hooper A.T., Butler J.M., Nolan D.J., et al. Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells. Cell Stem Cell 2009, 4:263-274.
43. Nordlander A., Mattsson J., Sundberg B., et al. Novel antibodies to the donor stem cell population CD34+/VEGFR-2+ are associated with rejection after hematopoietic stem cell transplantation. Transplantation 2008, 86:686-696.
44. + cell dose and disease status. Biol Blood Marrow Transplant 2009, 15:632-638.